JP Morgan Chase
IOVA icon

JP Morgan Chase’s Iovance Biotherapeutics IOVA Stock Holding History

JP Morgan Chase’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-50,000
Closed -$470K – 7557
2024
Q3 		$470K Buy
50,000
+36,000
+257% +$341K ﹤0.01% 4936
2024
Q2 		$112K Buy
+14,000
New +$150K ﹤0.01% 5455
2021
Q4 		– Sell
-33,800
Closed -$834K – 6794
2021
Q3 		$834K Buy
+33,800
New +$796K ﹤0.01% 4437
2020
Q2 		– Sell
-60,500
Closed -$1.81M – 5526
2020
Q1 		$1.81M Buy
+60,500
New +$1.6M ﹤0.01% 3046

Other funds holding IOVA

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
ICM
Invenomic Capital Management Boston, Massachusetts $2.18B AUM 0.03% 1-Year Est. Return

JP Morgan Chase's IOVA Position: Q1 2026 in Review

JP Morgan Chase reduced its Iovance Biotherapeutics (IOVA) stake by 17% in Q1 2026, selling an estimated $1.6M and leaving 2,500,624 shares worth $8.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2850.

JP Morgan Chase first reported a position in IOVA in Q4 2015 and has held it in 40 quarters since. The position peaked at $65M in Q1 2024. 285 funds tracked by Wall St. Rank hold IOVA as of Q1 2026.

  • JP Morgan Chase held 2,500,624 shares of Iovance Biotherapeutics worth $8.3M as of Q1 2026.
  • JP Morgan Chase sold 500,878 Iovance Biotherapeutics shares in Q1 2026, an estimated $1.6M.
  • Iovance Biotherapeutics made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #2850 holding.
  • JP Morgan Chase first reported a position in Iovance Biotherapeutics in Q4 2015 and has held it in 40 quarters since.
  • JP Morgan Chase's Iovance Biotherapeutics position peaked at $65M in Q1 2024.
  • 285 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.